While drug developers are eager to produce more effective drugs, deeper insight into the patient journey from diagnosis to treatment has attracted great interest. Taking non-small cell lung cancer (NSCLC), Purplelab and Genentech will explore how to use RWD to eliminate blind spots in the patient’s journey – Every stage from clinical development to market entry is informed of the life cycle of the drug.
The webinar will include executives from Purplelab and Dr. Ben Freiberg, the GCS GCS computing catalyst led by the main information system of the main information system. Genentech is owned by Roche.
The conversation points that the webinar will introduce include:
- How do pharmaceutical companies use RWD for NSCLC patient journeys?
- What is the “typical” patient journey of NSCLC?
- Draw the subtle parts of the patient’s journey
- The value of social determinants of health data
- Addressing socioeconomic barriers that may hinder clinical trial participation
- Use RWD to improve clinical trial recruitment, clinical endpoints and inform market access strategies
To sign up for a webinar to eliminate blind spots in the patient journey, scheduled on May 22 from 1-2 pm, please fill out the following form:
photo: Eugene Mymrin, Getty Images
